Pathology and Oncology Research (Jun 2023)
Tumor subtypes and signature model construction based on chromatin regulators for better prediction of prognosis in uveal melanoma
- Yue Li,
- Yue Li,
- Yue Li,
- Yue Li,
- Chao Xiong,
- Chao Xiong,
- Chao Xiong,
- Chao Xiong,
- Li Li Wu,
- Li Li Wu,
- Li Li Wu,
- Li Li Wu,
- Bo Yuan Zhang,
- Bo Yuan Zhang,
- Bo Yuan Zhang,
- Bo Yuan Zhang,
- Sha Wu,
- Sha Wu,
- Sha Wu,
- Sha Wu,
- Yu Fen Chen,
- Yu Fen Chen,
- Yu Fen Chen,
- Yu Fen Chen,
- Qi Hua Xu,
- Qi Hua Xu,
- Qi Hua Xu,
- Qi Hua Xu,
- Hong Fei Liao,
- Hong Fei Liao,
- Hong Fei Liao,
- Hong Fei Liao
Affiliations
- Yue Li
- School of Ophthalmology and Optometry, Nanchang University, Nanchang, Jiangxi, China
- Yue Li
- Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, China
- Yue Li
- National Clinical Research Center for Ocular Diseases Jiangxi Province Division, Nanchang, Jiangxi, China
- Yue Li
- Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, Jiangxi, China
- Chao Xiong
- School of Ophthalmology and Optometry, Nanchang University, Nanchang, Jiangxi, China
- Chao Xiong
- Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, China
- Chao Xiong
- National Clinical Research Center for Ocular Diseases Jiangxi Province Division, Nanchang, Jiangxi, China
- Chao Xiong
- Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, Jiangxi, China
- Li Li Wu
- School of Ophthalmology and Optometry, Nanchang University, Nanchang, Jiangxi, China
- Li Li Wu
- Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, China
- Li Li Wu
- National Clinical Research Center for Ocular Diseases Jiangxi Province Division, Nanchang, Jiangxi, China
- Li Li Wu
- Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, Jiangxi, China
- Bo Yuan Zhang
- School of Ophthalmology and Optometry, Nanchang University, Nanchang, Jiangxi, China
- Bo Yuan Zhang
- Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, China
- Bo Yuan Zhang
- National Clinical Research Center for Ocular Diseases Jiangxi Province Division, Nanchang, Jiangxi, China
- Bo Yuan Zhang
- Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, Jiangxi, China
- Sha Wu
- School of Ophthalmology and Optometry, Nanchang University, Nanchang, Jiangxi, China
- Sha Wu
- Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, China
- Sha Wu
- National Clinical Research Center for Ocular Diseases Jiangxi Province Division, Nanchang, Jiangxi, China
- Sha Wu
- Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, Jiangxi, China
- Yu Fen Chen
- School of Ophthalmology and Optometry, Nanchang University, Nanchang, Jiangxi, China
- Yu Fen Chen
- Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, China
- Yu Fen Chen
- National Clinical Research Center for Ocular Diseases Jiangxi Province Division, Nanchang, Jiangxi, China
- Yu Fen Chen
- Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, Jiangxi, China
- Qi Hua Xu
- School of Ophthalmology and Optometry, Nanchang University, Nanchang, Jiangxi, China
- Qi Hua Xu
- Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, China
- Qi Hua Xu
- National Clinical Research Center for Ocular Diseases Jiangxi Province Division, Nanchang, Jiangxi, China
- Qi Hua Xu
- Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, Jiangxi, China
- Hong Fei Liao
- School of Ophthalmology and Optometry, Nanchang University, Nanchang, Jiangxi, China
- Hong Fei Liao
- Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, China
- Hong Fei Liao
- National Clinical Research Center for Ocular Diseases Jiangxi Province Division, Nanchang, Jiangxi, China
- Hong Fei Liao
- Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, Jiangxi, China
- DOI
- https://doi.org/10.3389/pore.2023.1610980
- Journal volume & issue
-
Vol. 29
Abstract
Background: Uveal Melanoma (UM) is the most prevalent primary intraocular malignancy in adults. This study assessed the importance of chromatin regulators (CRs) in UM and developed a model to predict UM prognosis.Methods: Gene expression data and clinical information for UM were obtained from public databases. Samples were typed according to the gene expression of CRs associated with UM prognosis. The prognostic key genes were further screened by the protein interaction network, and the risk model was to predict UM prognosis using the least absolute shrinkage and selection operator (LASSO) regression analysis and performed a test of the risk mode. In addition, we performed gene set variation analysis, tumor microenvironment, and tumor immune analysis between subtypes and risk groups to explore the mechanisms influencing the development of UM.Results: We constructed a signature model consisting of three CRs (RUVBL1, SIRT3, and SMARCD3), which was shown to be accurate, and valid for predicting prognostic outcomes in UM. Higher immune cell infiltration in poor prognostic subtypes and risk groups. The Tumor immune analysis and Tumor Immune Dysfunction and Exclusion (TIDE) score provided a basis for clinical immunotherapy in UM.Conclusion: The risk model has prognostic value for UM survival and provides new insights into the treatment of UM.
Keywords
